Abstract: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination.

Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.

Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.

Abstract: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination.

Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.

Abstract: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination.

Abstract: The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies.

Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.

Abstract: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, and a polynucleotide encoding the binding molecule. The invention also provides an expression vector comprising the polynucleotide, an expression system comprising a polynucleotide capable of producing a binding molecule, as well as an isolated host cell comprising the expression system for producing the binding molecule. The invention also provides for compositions comprising the LINGO binding molecules and the use of binding molecule compositions as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity. The invention further provides for a method of treatment of diseases associated with axonal degeneration and demyelination.

Abstract: The present invention is directed to the preparation and use of a collection of antibody heavy chain complementarity determining region 3 (HCDR3) members, where diversity of the collection is a function of the length of the HCDR3 members. The diversity of the collection of HCDR3 regions substantially represents the natural amino acid distribution of HCDR3 in the human repertoire. This natural amino acid distribution can be represented by biasing the complete random distribution of amino acids, accordingly, in the HCDR3 encoding DNA sequence by using trinucleotide mutagenesis (TRIM) technology. A collection of HCDR3 members of the invention each can be comprised within a variable region of an antibody (or fragment thereof) to form a library of synthetic antibodies or antibody fragments. The invention also provides nucleic acid molecules encoding such diverse collection and methods of making and using the same.

Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.

Abstract: A tricistronic vector (i.e., a vector capable of expressing three exogenous genes, which are not fused together, under the control of one promoter) effectively can encode an immunoglobulin-presenting polypeptide and two immunoglobulin (Ig) polypeptides. The encoded Ig-presenting polypeptide is able to associate with at least one of the Ig polypeptides via co-expressed associating agents. A vector according to the present invention particularly is suited for phage display technology, e.g., when the Ig-presenting polypeptide is a phage coat protein and the Ig polypeptides associate to form a Fab.

Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.

Abstract: Antibodies and fragments that bind to the protein target c-Met, particularly to epitopes located in the c-Met extracellular domain, are provided, as are methods of use of the antibodies and kits, for treating an unwanted cell, in particular, a cell associated with a c-Met-related condition such as a cancer, a metastasis, or an inflammatory condition.

Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis.

Abstract: The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat disease related to bone abnormalities such as osteoporosis. An embodiment of the invention herein provides an antibody or a functional protein comprising an antigen-binding portion of said antibody for a target in sclerostin polypeptide, characterized in that the antibody or functional protein specifically binds to sclerostin polypeptide and can increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal.

Abstract: The invention relates to recombinant polypeptides, in particular antibodies or antibody fragments that bind Ed-B-isoforms of fibronectin and can block their function. In addition, the diagnostic and pharmaceutical application of the polypeptides according to the invention is disclosed.

Abstract: The present invention relates to methods for the formation of inter-molecular disulphide bonds, including (poly)peptides/proteins, nucleic acids, vectors, host cells and bacteriophages used in these methods. Furthermore the invention relates to the use of this method for the improved display of (poly)peptides/proteins on the surface of bacteriophage particles.

Abstract: The present invention provides a binding molecule which is capable of binding to the rat, cynomolgus monkey and human LINGO polypeptide, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment to promote axonal regeneration/plasticity; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with axonal degeneration and demyelination.

Abstract: Antibodies and fragments that bind to the protein target c-Met, particularly to epitopes located in the c-Met extracellular domain, are provided, as are methods of use of the antibodies and kits, for treating an unwanted cell, in particular, a cell associated with a c-Met-related condition such as a cancer, a metastasis, or an inflammatory condition.